Hudbay Minerals Inc. Ordinary Shares (Canada) vs Inovio Pharmaceuticals Inc — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $26.07 (market cap $11.24B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Hudbay Minerals Inc. Ordinary Shares (Canada) is far larger — about 100.2× Inovio Pharmaceuticals Inc's market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 1 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| HBM | INO | |
|---|---|---|
Market Cap | $11.24B | $112.19M |
Volume | 4,316,374 | 3,201,278 |
Sector | Basic Materials | Health |
52-Week High | $31.87 | $2.65 |
52-Week Low | $14.58 | $0.66 |
Typical Hold Time | 1 Days | 43 Days |
Enterprise Value | $11.30B | $83.51M |
Dividend Yield | 0.11% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →